AI-generated analysis. Always verify with the original filing.
Candel Therapeutics, Inc. entered into a purchase and sale agreement on February 19, 2026, announced via press release. The Company also provided preliminary cash and cash equivalents as of December 31, 2025.
Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement. On February 19, 2026, Candel Therapeutics, Inc. (the “Company”) announced its entry into a purchase and sale agree
by reference. Item 7.01. Regulation FD Disclosure. On February 19, 2026, the Company issued a press release announcing the Purchase Agreement described above. A
of this Current Report (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang
. Other Events. The Company is providing the following information about its preliminary cash and cash equivalents as of December 31, 2025. Based upon prelimina
. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated February 19, 2026. 104 Cover Page Interactive Data File (e
Material Agreement